Vandetanib Patent Expiration
Vandetanib is Used for treating symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic. It was first introduced by Genzyme Corp
Vandetanib Patents
Given below is the list of patents protecting Vandetanib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Caprelsa | US8067427 | Pharmaceutical compositions comprising ZD6474 | Aug 08, 2028 | Genzyme Corp |
| Caprelsa | US8642608 | Quinazoline derivatives as VEGF inhibitors |
Feb 06, 2022
(Expired) | Genzyme Corp |
| Caprelsa | US7173038 | Quinazoline derivatives as VEGF inhibitors |
Aug 14, 2021
(Expired) | Genzyme Corp |
| Caprelsa | USRE42353 | Quinazoline derivatives and pharmaceutical compositions containing them |
Sep 23, 2017
(Expired) | Genzyme Corp |
Vandetanib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List